Trial site
Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University)
Nanjing, 210029, ChinaNot linked to an institution yet
- 14running trials
- 5closed trials
The trials here
What the 19 trials at this site are about, from their registry records.
- Phase
- Phase 39 trials
- Phase 25 trials
- Phase 41 trial
- Status
- Active, not recruiting6 trials
- Not yet recruiting5 trials
- Completed3 trials
- Recruiting3 trials
- Terminated2 trials
- Lead sponsor
- Hoffmann-La Roche8 trials
- Changzhou No.2 People's Hospital3 trials
- Alebund Pharmaceuticals1 trial
- First Teaching Hospital of Tianjin University of Traditional Chinese Medicine1 trial
- LeonaBio1 trial
- and 5 more
Running trials
Not yet recruiting
Pirtobrutinib+Sonrotoclax(PS) Regimen in the Treatment of B-Cell Lymphoma
NCT07744750· Phase 2· Changzhou No.2 People's Hospital· Source
Contact: Huayuan Zhu
Not yet recruiting
Pirtobrutinib+Pola-R-CHP for Newly Diagnosed Non-GCB DLBCL
NCT07744724· Phase 2· Changzhou No.2 People's Hospital· Source
Contact: Jianyong Li, PhD
Not yet recruiting
Pirtobrutinib + R-CHOP for Untreated Non-GCB DLBCL
NCT07744737· Phase 2· Changzhou No.2 People's Hospital· Source
Contact: Jianyong Li
Not yet recruiting
Effect of Acupuncture on Psychoneurological Symptom Cluster in Breast Cancer Survivors
NCT07481903· First Teaching Hospital of Tianjin University of Traditional Chinese Medicine· Source
Contact: Jing Lu
Not yet recruiting
A Prospective, Multicenter, Open-label, Randomized Clinical Trial to Evaluate the Efficacy, Durability, and Safety of Aflibercept 8mg in Different Treatment Regimens in Chinese Patients With Polypoidal Choroidal Vasculopathy (PCV)
NCT07365371· Phase 4· Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine· Source
Contact: Weiwei Zhang
Recruiting
Immunotheray Combined With Simvastatin and Target Therapy and Chemotharepy for Advanced Colorectal Cancer
NCT07718490· Phase 2· The First Affiliated Hospital with Nanjing Medical University· Source
Contact: Yanhong Gu
Recruiting
A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China
NCT06933472· Phase 3· Alebund Pharmaceuticals· Source
Contact: Huijuan Mao, M.D.
Active, not recruiting
SHR-8068 in Combination With Adebrelimab, Bevacizumab, and Platinum-Based Chemotherapy as First-line Treatment in Patients With Advanced Biliary Tract Cancer
NCT06465563· Phase 2· Suzhou Suncadia Biopharmaceuticals Co., Ltd.· Source
Active, not recruiting
Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study)
NCT06439576· Hoffmann-La Roche· Source
Recruiting
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
NCT05696626· Phase 3· LeonaBio· Source
Contact: Yongmei Yin
Active, not recruiting
A Study to Evaluate the Effectiveness and Safety of Polatuzumab in Real World Clinical Practice Among Adult Chinese Participants With Diffuse Large B-Cell Lymphoma
NCT05954910· Hoffmann-La Roche· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
NCT05296798· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
NCT04770896· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma
NCT04712643· Phase 3· Hoffmann-La Roche· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error